相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Updated epidemiology of gastrointestinal cancers in East Asia
Junjie Huang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)
Drugging p53 in cancer: one protein, many targets
Ori Hassin et al.
NATURE REVIEWS DRUG DISCOVERY (2023)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G. Fakih et al.
LANCET ONCOLOGY (2022)
The complexity of p53-mediated metabolic regulation in tumor suppression
Yanqing Liu et al.
SEMINARS IN CANCER BIOLOGY (2022)
Smart PdH@MnO2 Yolk-Shell Nanostructures for Spatiotemporally Synchronous Targeted Hydrogen Delivery and Oxygen-Elevated Phototherapy of Melanoma
Wandong Wang et al.
ACS NANO (2022)
length Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials
Meimei Wang et al.
ACTA BIOMATERIALIA (2022)
Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer
Jashodeep Datta et al.
ONCOGENE (2022)
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Chi Chun Wong et al.
NATURE COMMUNICATIONS (2022)
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition
Jiang Li et al.
NATURE CANCER (2022)
A high-throughput screening identifies ZNF418 as a novel regulator of the ubiquitin-proteasome system and autophagy-lysosomal pathway
Sonia R. Singh et al.
AUTOPHAGY (2021)
Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy
Boyi Niu et al.
BIOMATERIALS (2021)
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Mukaddes Izci et al.
CHEMICAL REVIEWS (2021)
A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells
Shiyang Shen et al.
NATURE NANOTECHNOLOGY (2021)
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Gongmin Zhu et al.
MOLECULAR CANCER (2021)
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao et al.
NATURE (2021)
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
A. Grothey et al.
ANNALS OF ONCOLOGY (2021)
Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8
Yunjiao Zhang et al.
BIOMATERIALS (2021)
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis
Michael P. Kim et al.
CANCER DISCOVERY (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis
Palanisamy Nallasamy et al.
GASTROENTEROLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer
Jashodeep Datta et al.
CLINICAL CANCER RESEARCH (2020)
Targeting the MAPK Pathway in KRAS-Driven Tumors
Matthias Drosten et al.
CANCER CELL (2020)
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Marta Schirripa et al.
CLINICAL COLORECTAL CANCER (2020)
Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties
Mizuho Nakayama et al.
NATURE COMMUNICATIONS (2020)
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Luisa F. Escobar-Hoyos et al.
CANCER CELL (2020)
Enhancing Chemotherapy of p53-Mutated Cancer through Ubiquitination-Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe-4 Nanoparticles
Jieying Qian et al.
ADVANCED FUNCTIONAL MATERIALS (2020)
Gain-of-function mutant p53 in cancer progression and therapy
Cen Zhang et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation
Jinchul Kim et al.
CANCER CELL (2019)
Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis
Eleonora Ingallina et al.
NATURE CELL BIOLOGY (2018)
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Kanaga Sabapathy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov et al.
NATURE REVIEWS CANCER (2018)
Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications
Jacek Zielonka et al.
CHEMICAL REVIEWS (2017)
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Robert P. Jones et al.
BRITISH JOURNAL OF CANCER (2017)
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
D. P. Modest et al.
ANNALS OF ONCOLOGY (2016)
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Alejandro Parrales et al.
NATURE CELL BIOLOGY (2016)
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth
Jiajun Zhu et al.
NATURE (2015)
BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function
Xuetian Yue et al.
ELIFE (2015)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Oliver D. K. Maddocks et al.
NATURE (2013)
Distinct Roles In Vivo for the Ubiquitin-Proteasome System and the Autophagy-Lysosomal Pathway in the Degradation of α-Synuclein
Darius Ebrahimi-Fakhari et al.
JOURNAL OF NEUROSCIENCE (2011)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics
Yili Yang et al.
CANCER RESEARCH (2007)